Newly named Azar adviser O'Brien defends pricing index

John O'Brien is taking over as the point person on the Trump administration's drug pricing strategy as its plans to tie Medicare Part B drug prices to an international reference pricing scheme have come under fire.

HHS Secretary Alex Azar named O'Brien senior adviser to the secretary for drug pricing reform Thursday,

Read the full 513 word article

User Sign In